Abl Diagnostics (ABLD) | Stock Overview & Key Data

What is ABLD's 52-week high and low?

In the last 52 weeks, Abl Diagnostics reached a high of €8.10 (on March 6, 2025) and a low of €2.40 (on December 23, 2024).

What is the market cap and P/E ratio for ABLD?

Curious about Abl Diagnostics's size and valuation? Its market capitalization stands at 86.82M. When it comes to valuation, the P/E ratio (trailing twelve months) is 535.00, and the forward P/E (looking ahead) is 90.00.

Does ABLD pay dividends? If so, what's the yield?

Yes, Abl Diagnostics is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.92%, and the company has paid an average of €0.11 per share annually over the past 3 years.

Who are Abl Diagnostics's main competitors or similar companies to consider before investing?

When looking at Abl Diagnostics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Equasens EQS	772.60M	Healthcare	Health Information Services	4.90%	-37.24%
Cegedim S.A CGM	143.17M	Healthcare	Health Information Services	-20.31%	-50.48%
Smaio S.A ALSMA	36.90M	Healthcare	Health Information Services	53.40%	79.95%
Intrasense S.A ALINS	15.22M	Healthcare	Health Information Services	-6.67%	-15.15%
Ama Corp Plc ALAMA	14.39M	Healthcare	Health Information Services	12.50%	-74.53%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Abl Diagnostics Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Abl Diagnostics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.00%, the Debt to Equity ratio from the most recent quarter is 34.10, and its Gross Profit Margin stands at 61.04%.

What is the recent revenue and earnings growth for ABLD?

Looking at Abl Diagnostics's growth, its revenue over the trailing twelve months (TTM) was €6M. Compared to the same quarter last year (YoY), quarterly revenue grew by -10.30%, and quarterly earnings saw a YoY growth of 135.50%.

How much of ABLD stock is held by insiders and institutions?

Wondering who owns Abl Diagnostics stock? Company insiders (like executives and directors) hold about 99.64% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.

For more common questions about our data, please visit our About Data page.